GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

Akari Therapeutics (FRA:CLA) Accounts Payable & Accrued Expense for Financial Companies


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.


Akari Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Accounts Payable & Accrued Expense for Financial Companies
Traded in Other Exchanges
Address
22 Boston Wharf Road, 7th Floor, Boston, MA, USA, 02210
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.